Ancora Advisors LLC bought a new stake in Editas Medicine Inc (NASDAQ:EDIT) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 4,000 shares of the company’s stock, valued at approximately $127,000.

A number of other institutional investors have also added to or reduced their stakes in the stock. Dupont Capital Management Corp bought a new stake in Editas Medicine during the 2nd quarter valued at $342,000. Raymond James Financial Services Advisors Inc. raised its holdings in Editas Medicine by 91.7% during the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 22,066 shares of the company’s stock valued at $791,000 after buying an additional 10,556 shares during the last quarter. First Trust Advisors LP bought a new stake in Editas Medicine during the 2nd quarter valued at $3,362,000. Chevy Chase Trust Holdings Inc. raised its holdings in Editas Medicine by 13.9% during the 2nd quarter. Chevy Chase Trust Holdings Inc. now owns 448,148 shares of the company’s stock valued at $16,057,000 after buying an additional 54,850 shares during the last quarter. Finally, State of Wisconsin Investment Board raised its holdings in Editas Medicine by 36.3% during the 2nd quarter. State of Wisconsin Investment Board now owns 47,300 shares of the company’s stock valued at $1,695,000 after buying an additional 12,600 shares during the last quarter. Hedge funds and other institutional investors own 68.79% of the company’s stock.

Shares of NASDAQ EDIT opened at $28.39 on Friday. The company has a debt-to-equity ratio of 0.15, a current ratio of 13.14 and a quick ratio of 13.13. Editas Medicine Inc has a 12 month low of $22.50 and a 12 month high of $45.02. The firm has a market capitalization of $1.46 billion, a price-to-earnings ratio of -9.53 and a beta of 3.21.

Editas Medicine (NASDAQ:EDIT) last issued its quarterly earnings data on Wednesday, November 7th. The company reported ($0.32) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.72) by $0.40. Editas Medicine had a negative net margin of 410.68% and a negative return on equity of 53.15%. The business had revenue of $14.52 million during the quarter, compared to analyst estimates of $9.83 million. During the same period in the prior year, the business earned ($0.64) EPS. The company’s revenue for the quarter was up 131.2% on a year-over-year basis. Equities research analysts expect that Editas Medicine Inc will post -2.18 EPS for the current year.

In other Editas Medicine news, CFO Andrew A. F. Hack sold 6,000 shares of the company’s stock in a transaction on Friday, October 26th. The shares were sold at an average price of $25.70, for a total value of $154,200.00. Following the completion of the transaction, the chief financial officer now directly owns 6,000 shares in the company, valued at approximately $154,200. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Katrine Bosley sold 12,000 shares of the company’s stock in a transaction on Monday, October 1st. The stock was sold at an average price of $31.02, for a total transaction of $372,240.00. Following the completion of the transaction, the chief executive officer now owns 1,246,732 shares of the company’s stock, valued at $38,673,626.64. The disclosure for this sale can be found here. Insiders sold a total of 66,284 shares of company stock valued at $1,958,175 over the last 90 days. Company insiders own 5.20% of the company’s stock.

A number of equities research analysts recently commented on EDIT shares. BidaskClub lowered shares of Editas Medicine from a “buy” rating to a “hold” rating in a report on Tuesday, October 2nd. Zacks Investment Research upgraded shares of Editas Medicine from a “hold” rating to a “buy” rating and set a $32.00 price target for the company in a report on Tuesday, November 13th. Raymond James started coverage on shares of Editas Medicine in a report on Friday, September 21st. They set an “outperform” rating and a $40.00 price target for the company. Finally, Guggenheim started coverage on shares of Editas Medicine in a report on Tuesday, October 9th. They set a “neutral” rating for the company. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $45.50.

TRADEMARK VIOLATION WARNING: This story was published by Watch List News and is owned by of Watch List News. If you are reading this story on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The correct version of this story can be accessed at https://www.watchlistnews.com/ancora-advisors-llc-buys-new-position-in-editas-medicine-inc-edit/2669446.html.

Editas Medicine Profile

Editas Medicine, Inc operates as a genome editing company. It focuses on treating patients with genetically defined diseases by correcting their disease causing genes. The company develops a proprietary genome editing platform based on CRISPR technology to target genetically defined diseases with an initial focus on debilitating illnesses where there are no approved treatments.

See Also: What is the balance sheet?

Institutional Ownership by Quarter for Editas Medicine (NASDAQ:EDIT)

Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.